'Net sales (including other operating income) of
Epigral has increased 19.63% to Rs 627.63 crore on account volume growth from
Derivative products.
Revenue contribution from Derivatives & Specialty business increased to 52%
in Q4FY25 vs 48% in Q4FY24. In Q4FY24,
realization for Caustic Soda and Epichlorohydrin improved. For other products
realizations remained flat, however realization of Hydrogen Peroxide dropped.
Sales volume of derivatives & specialty business grew but total sales
volume remained constant. Captive consumption of Chlorine increased to 76%.
Operating profit margin has declined from 29.62% to
27.62%, leading to 11.58% rise in operating profit to Rs 173.38 crore.
Raw material cost as a % of total sales (net
of stock adjustments) increased from 51.42% to 51.97%. Employee cost increased from 4.81% to
4.98%. Other expenses rose from 14.50%
to 15.17%. Power and Oil fuel cost r...
Pleaselogin & subscribe to view the full report.
More Reports
|
|